SOX2 has the potential to serve as a biomarker for predicting the prognosis of CCA. Moreover, the PI3K/HDAC pathway can be considered as a target pathway for treating this disease. Furthermore, genes such as NNMT, GSTT1, SPTSSB, and RARRES1 might also be potential targets for therapeutic interventions. This evidence concerns the gene RARRES1 and cholangiocarcinoma.